Why Is BIOCRYST PHARMACEUTI (BCRX) Stock Down Today?

BioCryst Pharmaceuticals (BCRX) stock fell 6.94% to $9.86 in early trading on May 19, 2026, following a mixed set of developments including a key earnings report and recent insider sales. The stock opened at $10.55 but declined throughout the session, hitting a low of $9.85 before settling near $9.86. The move came despite strong quarterly revenue and guidance affirmation.

What Happened

BioCryst reported Q2 2026 earnings with revenue of $218.25 million, exceeding the $182.51 million estimate. ORLADEYO revenue reached $158.2 million, showing 10% growth and a successful pediatric launch. The company reaffirmed its full-year 2026 sales guidance of $635 million to $660 million, slightly below the $666.2 million estimate. Despite these positive fundamentals, the stock declined as investors appeared to weigh the company’s continued unprofitability. BioCryst remains unprofitable with a TTM EPS of -1.68 and a net margin of -40.9%. Two recent insider sales totaling $697,000 were also reported, with the most recent on May 19.

What The Data Shows

The stock traded at 0.4 times its 3-month average volume, with 1.7 million shares changing hands. It is currently within its 52-week range of $6.00 to $11.22. Analyst coverage remains mixed: RBC Capital and Wedbush both maintain Outperform ratings but have lowered their price targets to $13 and $20, respectively. Meanwhile, JPMorgan has reinstated a Neutral rating with a $12 price target. The 30-day average sentiment score is 58 out of 100, improving to 65 in the last seven days.

What To Watch

BioCryst will not report earnings again until Q3 2026. Investors should monitor coverage breadth and any further guidance updates, as well as insider activity in the coming weeks.